Viatris Inc. (VTRS)
VTRS moved a median of +0.04% 30 minutes after news, and +0.10% by the close. How VTRS actually reacts to news — the realized, point-in-time move the market made, measured across 1,320 labeled events over the last three years with zero look-ahead.
VTRS’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 50% | 1,317 |
| 30-min | +0.04% | 50% | 1,318 |
| 60-min | +0.14% | 56% | 1,318 |
| to close | +0.10% | 51% | 1,317 |
| Middle 50% of VTRS reactions | -0.68% to +0.61% |
|---|---|
| Median reaction (30-min) | +0.04% |
| Measured reactions | 1,320 |
Half of all Viatris Inc. news events land between -0.68% and +0.61% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when VTRS moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to VTRS's baseline. Nothing else.
Recent VTRS events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Viatris Receives U.S. FDA Approval for RYZUMVI® for the Treatment of Presbyopia | Press release | PR Newswire | +0.11% | -2.09% | |
| Form 8-K Viatris Inc For: Oct 08 | SEC filing · Form 8-K | SEC EDGAR | +0.17% | +1.04% | |
| Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies | Press release | PR Newswire | +0.17% | +1.04% | |
| Viatris to Report Third-Quarter 2026 Financial Results on November 5, 2026 | Press release | PR Newswire | -0.95% | -1.18% | |
| Viatris Recognized by Forbes as One of the World's Best Employers for the Sixth Consecutive Year | Press release | PR Newswire | +0.20% | +1.29% | |
| Viatris Announces Approval of WAKIX® (Pitolisant) in Japan, a First-in-Class Treatment for Narcolepsy and Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea Syndrome | Press release | PR Newswire | +0.33% | +2.04% | |
| Form 10-Q Viatris Inc For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.48% | -0.30% | |
| Form 8-K Viatris Inc For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | -1.49% | -10.25% | |
| Viatris Reports Second-Quarter 2026 Financial Results | Press release | PR Newswire | -1.49% | -10.25% | |
| Viatris Announces Quarterly Dividend | Press release | PR Newswire | -1.36% | +0.23% | |
| Viatris Receives U.S. FDA Approval for Gwyn Lo™, a Once-Weekly Contraceptive Patch | Press release | PR Newswire | +0.20% | -0.67% | |
| Form 8-K Viatris Inc For: Jul 01 | SEC filing · Form 8-K | SEC EDGAR | +0.12% | +2.58% | |
| Viatris to Report Second-Quarter 2026 Financial Results on August 6, 2026 | Press release | PR Newswire | +0.13% | +0.94% | |
| Viatris Announces Positive Top-Line Results from Phase 3 Study of VR-205 in Japanese Adults with Primary Immunoglobulin A Nephropathy | Press release | PR Newswire | +1.04% | -0.61% | |
| Form 8-K Viatris Inc For: Jun 17 | SEC filing · Form 8-K | SEC EDGAR | +0.49% | -0.07% | |
| Viatris Recognized as One of the 2026 Best Workplaces™ in Canada | Press release | Canada Newswire | -0.03% | -1.96% | |
| Form 8-K Viatris Inc For: Jun 12 | SEC filing · Form 8-K | SEC EDGAR | -0.03% | -1.96% | |
| U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute Pain | Press release | PR Newswire | +0.18% | -0.36% | |
| Form 8-K Viatris Inc For: May 15 | SEC filing · Form 8-K | SEC EDGAR | +0.18% | -0.36% | |
| Form 10-Q Viatris Inc For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.20% | -1.21% | |
| Form 8-K Viatris Inc For: May 07 | SEC filing · Form 8-K | SEC EDGAR | +2.83% | +3.63% | |
| Viatris Reports First-Quarter 2026 Financial Results | Press release | PR Newswire | +2.83% | +3.63% | |
| Viatris to Present at the Bank of America Securities 2026 Healthcare Conference | Press release | PR Newswire | +0.20% | -1.21% | |
| Viatris Announces Quarterly Dividend | Press release | PR Newswire | +3.10% | +4.65% | |
| Form 8-K Viatris Inc For: May 01 | SEC filing · Form 8-K | SEC EDGAR | +3.10% | +4.65% | |
| Viatris Announces Chief Financial Officer Transition | Press release | PR Newswire | +3.10% | +4.65% | |
| Viatris Announces Several Data Presentations on Investigational Low-Dose Estrogen Combined Hormonal Contraceptive Weekly Patch at the 2026 American College of Obstetricians and Gynecologists Annual Clinical & Scientific Meeting | Press release | PR Newswire | -0.67% | +0.60% | |
| Viatris to Report First Quarter 2026 Financial Results on May 7, 2026 | Press release | PR Newswire | +0.07% | +3.36% | |
| Viatris Announces Multiple Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting | Press release | PR Newswire | -0.91% | -1.97% | |
| Form ARS Viatris Inc For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.11% | +0.60% | |
| Form DEF 14A Viatris Inc For: May 15 | SEC filing · Form DEF | SEC EDGAR | +0.11% | +0.60% | |
| Form DEFA14A Viatris Inc | SEC filing · Form DEFA14A | SEC EDGAR | +0.11% | +0.60% | |
| Viatris Advances Innovative Portfolio with Approval of Effexor® in Japan for Adults with Generalized Anxiety Disorder (GAD) | Press release | PR Newswire | -0.45% | -0.75% | |
| Viatris to Outline its Vision for Sustained Revenue and Earnings Growth Through 2030 | Press release | PR Newswire | -2.33% | -1.82% | |
| Form 10-K Viatris Inc For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +1.98% | -1.52% | |
| Form 8-K Viatris Inc For: Feb 23 | SEC filing · Form 8-K | SEC EDGAR | -0.31% | -5.22% | |
| Viatris Maintains Dividend Policy for 2026 and Announces Quarterly Dividend | Press release | PR Newswire | -0.31% | -5.22% | |
| Viatris Reports Fourth-Quarter and Full-Year 2025 Financial Results | Press release | PR Newswire | -0.31% | -5.22% | |
| FDA Accepts Viatris Supplemental New Drug Application for MR-141 (Phentolamine Ophthalmic Solution 0.75%) for the Treatment of Presbyopia | Press release | PR Newswire | +1.02% | -0.68% | |
| Form 8-K Viatris Inc For: Jan 29 | SEC filing · Form 8-K | SEC EDGAR | +1.76% | +3.38% | |
| Viatris Appoints Matthew J. Maletta as Chief Legal Officer | Press release | PR Newswire | -0.07% | +0.00% | |
| Viatris to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026, and Host Investor Event on March 19, 2026 | Press release | PR Newswire | +1.76% | +3.38% | |
| Viatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa® (Sotagliflozin) for the Treatment of Heart Failure | Press release | PR Newswire | -0.63% | -0.63% | |
| Viatris Appoints Lara Ramsburg as Chief People and Corporate Affairs Officer | Press release | PR Newswire | +0.40% | +1.70% | |
| Viatris Provides Pipeline Update on Four Regulatory Milestones | Press release | PR Newswire | +0.26% | +2.23% | |
| Viatris to Present at the 44th Annual J.P. Morgan Healthcare Conference | Press release | PR Newswire | +0.26% | +1.83% | |
| Viatris Recognized as 2025 Best Workplaces™ in Ontario and for Giving Back | Press release | Canada Newswire | +0.00% | -0.60% | |
| Form 8-K Viatris Inc For: Dec 08 | SEC filing · Form 8-K | SEC EDGAR | +0.64% | +0.91% | |
| Viatris Announces Agreement to Monetize its Equity Stake in Biocon Biologics Limited | Press release | PR Newswire | +0.64% | +0.91% | |
| Form 8-K Viatris Inc For: Dec 05 | SEC filing · Form 8-K | SEC EDGAR | +0.64% | +0.91% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the VTRS section they belong to.
Where else VTRS is measured.
VTRS earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Viatris Inc.'s median reaction calculated?
Every labeled VTRS news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 1,320 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 50% of VTRS's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does VTRS's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.